What is BBOT's current stock price?

BBOT (BridgeBio Oncology Therapeutics Inc.) is currently trading at $8.55 with a market cap of $684.9M.

What sector is BridgeBio Oncology Therapeutics Inc. in?

BridgeBio Oncology Therapeutics Inc. (BBOT) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is BBOT a good stock to buy?

Analysts have a Buy consensus on BBOT with a price target of $22.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

BBOT BridgeBio Oncology Therapeutics Inc.

Healthcare

$8.55-6.15%ClosedMarket Cap: $684.9M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

1.84

P/S

0.00

EV/EBITDA

-3.78

DCF Value

$11.88

FCF Yield

-25.2%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-61.5%

ROA

-36.9%

ROIC

-45.0%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-42.1M	$—
Q4 null	$0.00	$-38.8M	$—
FY null	$0.00	$-134.0M	$—
Q3 null	$0.00	$-44.8M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$22.00

Target (Median)

$23.00

Target Range

$18.00 - $24.00

3 Strong Buy7 Buy0 Hold0 Sell0 Strong Sell

HC Wainwright & Co.Buy

2026-03-06

WedbushOutperform

2025-12-11

OppenheimerOutperform

2025-11-13

Trading Activity

Insider Trades

View All

Elmelech Idanofficer: COO & Principal Financial Ofcr

SellTue May 12

Beltran Pedrodirector, officer: President and CEO

SellTue May 12

Mehra Uneekother: Former Officer

SellTue May 05

Ben Yongofficer: Chief Med & Dev Officer

SellTue May 05

Beltran Pedrodirector, officer: President and CEO

SellTue May 05

Latest News

BBOT Presents Preclinical Data Showing RAS:PI3Kα Breaker BBO-10203 Inhibits PI3Kα/AKT Signaling in HER2AMP Models at the AACR Annual Meeting 2026GlobeNewsWire · Tue Apr 21

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

0.22

BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company developing next-generation small molecule therapeutics targeting RAS and PI3Kα malignancies, which are prevalent oncogenes in human tumors. Initially formed as a subsidiary of BridgeBio Pharma, it focuses on precision oncology with a pipeline that includes BBO-8520, BBO-10203, and BBO-11818 programs targeting KRAS and PI3K pathways. The company recently went public through a business combination with Helix Acquisition Corp. II, raising approximately $450 million to advance clinical development. The CEO is Dr. Eli Wallace, and the CSO is Dr. Pedro Beltran.

Peers

KOD

OCS